Topline data were announced from a phase 3 trial evaluating tarlatamab-dlle (Imdelltra ®) for the treatment of small cell lung cancer (SCLC) in patients who progressed on or after a single line of ...

One clinical trial of Opdivo involved adults with squamous non-small cell lung cancer (NSCLC). Researchers found that people with squamous NSCLC who took Opdivo had a lower risk of death compared ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered ... 1 According to the American Cancer Society, lung cancer remains the leading cause of cancer-related death in ...

A pill has been shown to halve the risk of death from a certain type of lung ... size-fits-all treatment for people with non-small cell lung cancer." Osimertinib is already authorised in dozens ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, ...

The drug has been specifically authorised in combination with etoposide and platinum chemotherapy to treat adult patients with extensive-stage small cell lung cancer (SCLC ... in a 25% reduction in ...

TTFields exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death. "The CE Mark approval for Optune Lua for metastatic non-small cell lung ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous non-small cell lung cancer ... progression or death by 43% versus ...

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs standard of care therapy. Topline data were announced from a phase 3 ...